Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 22.
doi: 10.1007/s13346-024-01726-3. Online ahead of print.

Development of FK506-loaded maleimide-functionalized cationic niosomes for prolonged retention and therapeutic efficacy in dry eye disease

Zhixin Guo #  1 , Yutong Song #  2 , Zhihong Liu  1 , Jiansheng Dai  1 , Zhenzhen Chen  1 , Xianquan Feng  1 , Wenhao Gao  1 , Lingjun Zeng  3 , Hongtao Song  4
Affiliations

Development of FK506-loaded maleimide-functionalized cationic niosomes for prolonged retention and therapeutic efficacy in dry eye disease

Zhixin Guo et al. Drug Deliv Transl Res. .

Abstract

Tacrolimus (FK506) is widely used in ocular diseases such as corneal transplantation-host disease, uveitis, conjunctivitis, and dry eye disease (DED). However, its low aqueous solubility and poor ocular retention pose challenges for its application in the eye diseases. This study developed a novel FK506-loaded maleimide-functionalized cationic niosomes (FK506 M-CNS), aiming to prolong the retention time of FK506 in the eye and enhance its therapeutic efficacy. FK506 M-CNS had a particle size of 87.69 ± 1.05 nm and zeta potential of 22.06 ± 1.01 mV. Results of histological evaluation through H&E staining and in vitro cytotoxicity of human corneal epithelial cells consistently revealed the excellent biocompatibility of FK506 M-CNS. FK506 M-CNS exhibited superior ocular retention compared to the market product Talymus®. FK506 M-CNS significantly alleviated the symptoms of DED and promoted the recovery of corneal epithelia. FK506 M-CNS group had the lowest expression levels of inflammatory factors associated with DED. These superiorities might be due to the electrostatic interaction between cationic niosomes and negatively charged mucin in the eye, and the covalent binding of maleimide with the thiol group in the mucin. The maleimide group improved the ocular retention and efficacy of FK506, but did not increase the toxicity. Results indicated that FK506 M-CNS had great potential as a nanopharmaceutical in the treatment of ocular diseases, and M-CNS could be a promising drug carrier for ophthalmic drug delivery systems.

Keywords: Cationic; Dry eye disease; Maleimide; Niosomes; Retention time; Tacrolimus.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Yi H, et al. Effectiveness of an ocular adhesive polyhedral oligomeric silsesquioxane hybrid thermo-responsive FK506 hydrogel in a murine model of dry eye. Bioactive Mater. 2022;9:77–91. https://doi.org/10.1016/j.bioactmat.2021.07.027 . - DOI
    1. Ou L, et al. A tissue-adhesive F127 hydrogel delivers antioxidative copper-selenide nanoparticles for the treatment of dry eye disease. Acta Biomater. 2024;175:353–68. https://doi.org/10.1016/j.actbio.2023.12.021 . - DOI - PubMed
    1. Stapleton F, TFOS DEWS II Epidemiology Report, et al. Ocul Surf. 2017;15:334–65. https://doi.org/10.1016/j.jtos.2017.05.003 .
    1. Modi D, et al. Formulation and development of tacrolimus-gellan gum nanoformulation for treatment of dry eye disease. Colloids Surf B Biointerfaces. 2022;211:112255. https://doi.org/10.1016/j.colsurfb.2021.112255 . - DOI - PubMed
    1. López-Machado A, et al. Development of lactoferrin-loaded liposomes for the management of Dry Eye Disease and ocular inflammation. Pharmaceutics. 2021;13(10):1698. https://doi.org/10.3390/pharmaceutics13101698 . - DOI - PubMed - PMC

LinkOut - more resources